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With the emergence of the COVID-19 viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or worsened disease course.While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection.Factors that should be considered when deciding whether to start or continue biologics include severity of underlying psoriasis or psoriatic arthritis; COVID-19 risk factors such as older age, cardiovascular disease, hypertension, lung disease, diabetes, or cancer; concomitant immunosuppressive medications or conditions; and risk of exposure to the COVID-19 virus based on geography, occupation, and living situation.Ultimately, treatment decisions should be made on an individualized basis based on dialogue between patient and provider.

Commentary {#Sec1}
==========

In late December 2019, the world was introduced to the novel coronavirus disease (COVID-19). As of March 2020, there were over 920,000 cases and 46,000 deaths worldwide, with these numbers expected to rise sharply. Upon review of 55,924 patients with COVID-19 \[[@CR1]\], the clinical presentation generally involved fever in 87.9%, dry cough in 67.7%, fatigue in 38.1%, sputum production in 33.4%, shortness of breath in 18.6%, and sore throat in 13.9%. Gastrointestinal symptoms have also been reported with diarrhea in 3.7% of patients and nausea or vomiting in 5% of patients. Patients with COVID-19 generally develop signs and symptoms on average 5--6 days after infection (range 1--14 days) [@CR1]. The goal of this article is to review the known clinical trial data on infection risk with biologic therapy for psoriasis and offer patient counseling recommendations based on the current available evidence.

There are currently 11 biologic therapies approved for psoriasis. These medications are engineered to target individual mediators of inflammation including tumor necrosis factor-alpha (TNFα), interleukin-17 (IL-17), and IL-23. Although the safety profiles of these biologic agents are generally preferable to those of traditional immunosuppressive therapies, there is concern that treatment with these agents may reduce resistance to infection. This concern is heightened during novel disease outbreaks and the resulting increased media coverage. As a result, patients are increasingly turning to healthcare providers for guidance regarding the use of biologic agents during disease outbreaks.

Given the novel nature and rapidly evolving knowledge of COVID-19, there are currently no specific data for how biologic therapy affects patients' risk of acquiring this coronavirus infection or COVID-19 outcomes. However, more general data on infection risk are available for psoriasis biologic agents from phase III clinical trial data. Infections typically reported in these studies include upper respiratory infections, influenza, sinusitis, urinary tract infection, opportunistic infections, and serious infections. Serious infections are defined as infections involving various organ systems that may lead to hospitalization or death including pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis, and prosthetic or post-surgical infection. Table [1](#Tab1){ref-type="table"} summarizes the rates of upper respiratory infections, rates of influenza, and risks of serious infections for all 11 currently approved biologic agents for psoriasis, as observed in phase III clinical trials. Overall these data reveal that on the whole, psoriasis biologics do not show substantial increases in infection risk compared to placebo, which is also consistent with long-term registry data [@CR2]. The safety signal appears especially clean for etanercept, ustekinumab, tildrakizumab, guselkumab, and risankizumab, although it is important to note that the data from these trials were derived from a relatively short period and do not fully reflect real-world settings.Table 1Rates of upper respiratory infection, influenza, and serious infection in the phase III clinical trials of US FDA-approved biologics for psoriasisMedication, year of FDA approval, mechanism of actionRates of URI (vs. placebo)Rates of influenza (vs. placebo)Rates of serious infections (vs. placebo)Adalimumab, 2002, TNFα inhibitorREVEAL [@CR7]REVEALREVEAL7.2% (40 mg) vs. 3.5% (placebo) at week 16NR0.6% (40 mg) vs. 1% (placebo) at week 16CHAMPION [@CR8]CHAMPIONCHAMPION28% (40 mg) vs. 20.8% (placebo) at week 16 for nasopharyngitis0% (40 mg) vs. 1.9% (placebo) at week 16 for viral infection0% (40 mg) vs. 0% (placebo) at week 16Etanercept, 2004 TNFα inhibitorTyring et. al. [@CR9]Tyring et. al. [@CR9]Tyring et. al. [@CR9]20.2/100 PY (50 mg) vs. 24.3/100 PY (placebo) through week 96NR1.2/100 PY (50 mg) vs. 1.5/100 PY (placebo) through week 96Papp et al. [@CR10]Papp et al. [@CR10]Papp et al. [@CR10]13% (50 mg) vs. 13% (25 mg) vs. 13% (placebo) at week 124% (50 mg) vs. 5% (25 mg) vs. 2% (placebo) at week 12 for "flu syndrome"NR (\< 5% reported in study)Leonardi et. al. [@CR11]Leonardi et. al. [@CR11]Leonardi et. al. [@CR11]5% (50 mg BIW) vs. 9% (25 mg BIW) vs. 10% (25 mg QWK) vs. 11% (placebo) at week 12NR (\< 5% reported in study)NR (\< 5% reported in study)Infliximab, 2006, TNFα inhibitorEXPRESS 1 [@CR12]EXPRESS 1EXPRESS 115% (5 mg/kg) vs. 16% (placebo) at week 24NRNREXPRESS 2 [@CR13]EXPRESS 2EXPRESS 216% (3 mg/kg) vs. 13.4% (5 mg/kg) vs. 14% (placebo) at week 14NRNRCertolizumab, 2018, PEGylated TNFα inhibitorCIMPASI 1 [@CR14]CIMPASI 1CIMPASI 19.1% (400 mg) vs. 7.4% (200 mg) vs. 5.9% (placebo) at week 16NR0% (400 mg) vs. 0% (200 mg) vs. 0% (placebo) at week 16CIMPASI 2 [@CR14]CIMPASI 2CIMPASI 25.7% (400 mg) vs. 4.4% (200 mg) vs. 4.1% (placebo) at week 16NR1.1% (400 mg) vs. 0% (200 mg) vs. 0% (placebo) at week 16CIMPACT \[[@CR28]\]CIMPACTCIMPACT3.6% (200 mg) vs. 10.5% (placebo) at week 12NR0% vs. 0% at week 12Ustekinumab, 2009, anti-IL-12/23PHOENIX 1 [@CR15]PHOENIX 1PHOENIX 17.1% (45 mg) vs. 6.3% (90 mg) vs. 6.3% (placebo) at week 12NR0% (45 mg) vs. 0.8% (90 mg) vs. 0.4% (placebo) at week 12PHOENIX 2 [@CR16]PHOENIX 2PHOENIX 24.4% (45 mg) vs. 2.9% (90 mg) vs. 3.4% (placebo) at week 12NR0% (45 mg) vs. 0.2% (90 mg) vs. 0.5% (placebo) at week 12Secukinumab, 2015, anti-IL-17AERASURE [@CR17]ERASUREERASURE3.7% (300 mg) vs. 4.1% (150 mg) 0% (placebo) at week 122% (300 mg) vs. 1.2% (150 mg) vs. 1.2% (placebo) at week 121% (300 mg) vs. 0.7% (150 mg) vs. 1.5% (placebo) at week 52FIXTURE [@CR17]FIXTURE2.1% (300 mg) vs. 3.1% (150 mg) vs. 0.9% (placebo) at week 121.1% (300 mg) vs. 0.6% (150 mg) vs. 0.3% (placebo) at week 52FEATURE [@CR18]5.1% (300 mg) vs. 5.1% (150 mg) vs. 8.5% (placebo) at week 12 for nasopharyngitisJUNCTURE [@CR19]Sinusitis: 5% (300 mg) vs. 1.6% (150 mg) vs. 0% (placebo); Nasopharyngitis: 31.7% (300 mg) vs. 23% (150 mg) vs. 16.4% (placebo) at week 12Brodalumab, 2017, anti-IL-17AMAGINE 1 [@CR20]AMAGINE 1AMAGINE 18.2% (140 mg Q2W) vs. 8.1% (210 mg Q2W) vs. 6.4% (placebo)NR0.9% (140 mg Q2W) vs. 0.5% (210 mg Q2W) vs. 0% (placebo) at week 124.5% (140 mg Q2W) vs. 1.2% (210 mg Q2W) at week 52AMAGINE 2 [@CR21]AMAGINE 2AMAGINE 2NRNRNRAMAGINE 3 [@CR21]AMAGINE 3AMAGINE 3NRNRNRIxekizumab, 2017, anti-IL-17AUNCOVER 1, 2, 3 (pooled) [@CR22]UNCOVER 1, 2, 3 (pooled)UNCOVER 1, 2, 3 (pooled)3.9% (Q4W) vs. 4.4% (Q2W) vs. 3.5% (placebo) at week 12NR0.7% (Q4W) vs. 0.4% (Q2W) vs. 0.4% (placebo) at week 1210% (IXE all exposure) at week 601.4% (IXE all exposure) at week 60Guselkumab, 2017, anti-IL-23VOYAGE 1 [@CR23]VOYAGE 1VOYAGE 17.6% (100 mg) vs. 5.2% (placebo) at week 16NR0% (100 mg) vs. 0% (placebo) at week 16VOYAGE 2 [@CR24]VOYAGE 2VOYAGE 23.2% (100 mg) vs. 4.0% (placebo) at week 16NR0.2% (100 mg) vs. 0.4% (placebo) at week 16Tildrakizumab, 2018, anti-IL-23RESURFACE 1 [@CR25]RESURFACE 1RESURFACE 13% (100 mg) vs. 5% (200 mg) vs. 6% (placebo) at week 12NR \< 1% (100 mg) vs. \< 1% (200 mg) vs. 0% (placebo) at week 12RESURFACE 2 [@CR25]RESURFACE 2RESURFACE 20% (100 mg) vs. 0% (200 mg) vs. 0% (placebo) at week 12NR0% (100 mg) vs. \< 1% (200 mg) vs. 1% (placebo) at week 12Risankizumab, 2019, anti-IL-23ULTIMMA-1 [@CR26]ULTIMMA-1ULTIMMA-1Part A: 5.59% (150 mg) vs. 1.96% (placebo) at week 16Part A: 6.58% (150 mg) vs. 5.88% (placebo) at week 16 viral upper respiratory infectionPart A: 0.3% (150 mg) vs. 0% (placebo) at week 16Part B: 10.10% (150 mg) vs. 8.25% (placebo) at weeks 16--52Part B: 13.47% (150 mg) vs. 15.46% (placebo) at weeks 16--52 for viral upper respiratory infectionPart B: 0.7% (150 mg) vs. 1% (placebo) at weeks 16--52ULTIMMA-2 [@CR26]ULTIMMA-2ULTIMMA-2Part A: 3.74% (150 mg) vs. 2.04% (placebo) at week 16Part A: 2.04% (150 mg) 1.02% (placebo) at week 16 for influenzaPart A: 1% (150 mg) vs. 0% (placebo) at week 16Part B: 8.25% (150 mg) vs. 9.57% (placebo) at weeks 16--52Part B: 1.37% (150 mg) vs. 2.13% (placebo) at weeks 16--52 for influenzaPart B: 0.7% (150 mg) vs. 0% (placebo) at weeks 16--52IMMHANCE [@CR27]IMMHANCEIMMHANCEPart A1: 1.47% (150 mg) vs. 5% (placebo) at week 16Part A1: 0.74% (150 mg) vs. 1% (placebo) at week 160% (150 mg) vs. 0% (placebo) at week 16 for viral infection, bronchitis, and bacterial meningitis*NR*  not reported, *NS* not significant, *PY* patient year

Biologic medications for psoriasis are meant to be taken continuously. There are risks to stopping biologic therapy since psoriasis flares and erythroderma may lead to poor quality of life and hospitalization. Also, stopping and restarting some biologic agents may result in reduced efficacy [@CR3], [@CR4]. On the other hand, given the absence of specific data on psoriasis biologics and COVID-19, which can potentially be fatal, a cautious approach is warranted. In particular, the presence of risk factors for COVID-19 mortality such as age \> 60, cardiovascular disease, hypertension, lung disease, diabetes, or cancer may alter the benefit--risk ratio for biologic therapy, particularly in the short term whereby biologic reduction or discontinuation may not lead to immediate disease flare [@CR5] (Table [2](#Tab2){ref-type="table"}).Table 2Considerations for use of psoriasis biologic medications during the COVID-19 pandemicFactors favoring biologic discontinuation or reduction in immunomodulatory regimenFactors favoring biologic continuationAny active infection, including COVID-19Young ageCOVID-19 risk factors including: age \> 60, cardiovascular disease, hypertension, lung disease, diabetes, or cancerNo COVID-19 high risk co-morbiditiesConcomitant immunosuppression (e.g., methotrexate, prednisone, cyclosporine)Biologic monotherapyImmunosuppressive condition (e.g., HIV)Severe underlying psoriasis or psoriatic arthritis, with history of rapid flares or unstable subtypes (pustular, erythrodermic)History of infections while on biologicNo concomitant immunosuppressive conditionsMild-to-moderate underlying psoriasisLow risk of exposure to COVID-19 virusHigh risk of exposure to COVID-19 virus (e.g., endemic area, healthcare worker, nursing home resident, household member or co-worker with COVID-19 infection)Long duration of COVID-19 pandemicShort duration of COVID-19 pandemic

Therefore, at the current time, the following guidance may be given to patients with psoriasis:All patients should be reminded to practice good infection prevention measures such as frequent hand washing, social distancing, and the use of telehealth resources when available.There is no evidence to recommend prophylactically stopping or postponing biologic therapy in all patients with psoriasis; however, patients should have individualized discussions with their medical providers taking into account the following factors:COVID-19 risk factors such as older age, cardiovascular disease, hypertension, lung disease, diabetes, or cancerSeverity of underlying psoriasis or psoriatic arthritisConcomitant immunosuppressive medications or conditionsRisk of exposure to COVID-19 based on occupation or living situationIf a reduction in immunosuppressive treatment is desired, options include:Temporary discontinuation of the biologicReduction in biologic dose frequencyTransition to an alternative biologicReduction or discontinuation of concomitant immunosuppressants (e.g., methotrexate)Increase in use of topical agents, home phototherapy, or other non-immunosuppressive medicationsPatients who test positive for COVID-19 infection should be advised to hold their biologic dose until their infection clears. This requires resolution of fever without the use of fever-reducing medications, improvement in respiratory symptoms (e.g., cough, shortness of breath), and two negative COVID-19 test performed 24 h apart. However, if COVID-19 retesting is not available, then a conservative approach would be to avoid restarting biologic therapy until 30 days after resolution of fever and respiratory symptoms. This estimate is based on a mean duration of COVID-19 viral shedding from illness onset of 20 days (range 8--37 days) in hospitalized patients [@CR6].The risks and benefits of initiating biologic therapy should be considered on an individual patient basis, according to the factors listed above.

It is important to remember that this is a novel, rapidly changing situation, and recommendations may change as more data become available. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. This worldwide pandemic of substantial human disease caused by a type of virus previously thought to be relatively benign highlights the perpetual challenge of emerging infectious diseases, the importance of long-term monitoring of patients on biologic therapy, and shared decision-making with patients on biologic therapy. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.
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